Content
Content
Team
Team
Companies
Companies
About
About
Products
Products
Signal
Brieflink
NFX Masterclass
Get our weekly newsletter that 321K+ startup teams read
Subscribe
Bio
35
Focus Areas
All Focus Areas
Cybersecurity
· 4
Bio
· 35
Gaming
· 6
AI
· 47
PropTech
· 5
Space
· 6
Fintech
· 5
Marketplaces
· 26
Crypto
· 18
Silicon Valley
· 6
Israel
· 11
Europe
· 4
LatAm
· 4
By Author
Anna Piñol
Anastasia Budinskaya
Daniel Museles
Valerie Osband Mahoney
Morgan Beller
Omri Amirav-Drory, Ph.D.
Pete Flint
Gigi Levy-Weiss
James Currier
Topics
Network Effects
· 35
Fundraising
· 29
Growth
· 123
Leadership
· 57
Investment Memos
· 65
Psychology
· 54
Announcements
· 28
By Type
All NFX Content
· 435
Videos
· 38
Podcasts
· 90
Essays
· 173
Bio · 35
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
“Find a Way to Break Reality”: How Centivax Brought a Universal Flu Vaccine to Clinic
In Vitro, In Vivo, In China: How Early-Stage Companies Are Reaching the Clinic Faster Than Ever
The Founder’s Guide to JPM
The AI Utopia Doesn’t Exist Without Bio
The Seasons of Fundraising
Women’s Health 2.0: Beyond Fertility
Longevity Can Save America
Why Don’t Billionaires Invest In Longevity?
Longevity’s First Blockbuster
Why Great Bioplatforms Will Always Win
The Race to 160
The Business Case for Longevity
A Scientific Approach To Your Company (And Your Life)
What I Wish I Knew as a Scientist-Founder
A Scientific Approach to VC
The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)
The NFX Bio Guide to JPM Success
Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery
The Future of Longevity: Keeping Healthy People Healthy
The 3 Waves of AI in Bio
Maximizing TechBio Deal Potential: Platform vs. Asset Deals
Deal or Die: Your 3-Part Guide to Business Development in TechBio
Tech Founders, Don’t Be Afraid of Bio
Featured
A Mammoth Becomes A Unicorn: Inside a Scientist-Founder’s Journey from Pre-Seed to Series D
“Find a Way to Break Reality”: How Centivax Brought a Universal Flu Vaccine to Clinic
In Vitro, In Vivo, In China: How Early-Stage Companies Are Reaching the Clinic Faster Than Ever
The Founder’s Guide to JPM
The AI Utopia Doesn’t Exist Without Bio
The Seasons of Fundraising
Women’s Health 2.0: Beyond Fertility
Longevity Can Save America
Why Don’t Billionaires Invest In Longevity?
Longevity’s First Blockbuster
Why Great Bioplatforms Will Always Win
The Race to 160
The Business Case for Longevity
A Scientific Approach To Your Company (And Your Life)
What I Wish I Knew as a Scientist-Founder
A Scientific Approach to VC
The Future of Longevity: The Battle Against Human Aging (An NFX Documentary)
The NFX Bio Guide to JPM Success
Why NFX Invested in Mana Bio: The TechBio Platform Using AI for Better Drug Delivery
The Future of Longevity: Keeping Healthy People Healthy
The 3 Waves of AI in Bio
Maximizing TechBio Deal Potential: Platform vs. Asset Deals
Deal or Die: Your 3-Part Guide to Business Development in TechBio
Tech Founders, Don’t Be Afraid of Bio
Load More Content
Subscribe for more Bio insights
Get our weekly newsletter that 321K+ startup teams read
Subscribe